Neumora Therapeutics (NMRA) Current Assets (2022 - 2026)

Neumora Therapeutics' Current Assets history runs 5 years deep, the most recent figure standing at $153.4 million for Q1 2026.

• In Q1 2026, Current Assets fell 39.8% year-over-year to $153.4 million; the TTM figure through Mar 2026 stood at $153.4 million (down 39.8% YoY), while the FY2025 annual figure was $190.5 million, down 39.33% from the prior year.
• Current Assets was $153.4 million for Q1 2026 at Neumora Therapeutics, down from $190.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $525.7 million in Q3 2023 to a low of $153.4 million in Q1 2026.
• Historically, Current Assets has averaged $324.5 million across 5 years, with a median of $331.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Assets increased 23.28% in 2023, then slumped 49.2% in 2025.
• A 5-year view of Current Assets shows it stood at $388.0 million in 2022, then advanced by 23.28% to $478.3 million in 2023, then tumbled by 34.34% to $314.1 million in 2024, then tumbled by 39.33% to $190.5 million in 2025, then declined by 19.47% to $153.4 million in 2026.
• The last three Current Assets figures came in at $153.4 million (Q1 2026), $190.5 million (Q4 2025), and $177.1 million (Q3 2025), per Business Quant data.